Myelodysplastic syndromes
BMS Acquires Orum’s ADC ORM-6151 for AML and MDS Treatment
Anika Sharma
Bristol Myers Squibb (BMS) has made a significant move in the field of antibody-drug conjugates (ADCs) by acquiring Orum Therapeutics’ ...
Magrolimab fails to improve survival in leukemia, Gilead halts trial
Anika Sharma
Another failure has occurred in Gilead Sciences’ $4.9 billion immuno-oncology wager. Following an ad hoc analysis of a phase 3 ...
FDA Grants Approval: Reblozyl’s Triumph Ushers in a New Dawn for Anemia Treatment
Anika Sharma
Bristol Myers Squibb has ushered in a breakthrough in the realm of medical advancements, announcing the FDA’s seal of approval ...
Gilead’s Magrolimab Faces Fresh Setback as FDA Issues Partial Clinical Hold
Anika Sharma
One month after Gilead Sciences made public its decision to halt a myelodysplastic syndromes (MDS) program centered around magrolimab, the ...
Magrolimab for myelodysplastic syndromes is discontinued by Gilead
SG Tylor
Source – Gilead Science Gilead Sciences has announced the discontinuation of its cancer antibody, magrolimab, in the treatment of blood ...
